562 related articles for article (PubMed ID: 31110217)
21. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
Shang Q; Xue L; Lu A; Jia Y; Zuo Y; Zeng H; Zhang L
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):392-399.e5. PubMed ID: 38429221
[TBL] [Abstract][Full Text] [Related]
23. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
24. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Ghorashian S; Lucchini G; Richardson R; Nguyen K; Terris C; Guvenel A; Oporto-Espuelas M; Yeung J; Pinner D; Chu J; Williams L; Ko KY; Walding C; Watts K; Inglott S; Thomas R; Connor C; Adams S; Gravett E; Gilmour K; Lal A; Kunaseelan S; Popova B; Lopes A; Ngai Y; Hackshaw A; Kokalaki E; Carulla MB; Mullanfiroze K; Lazareva A; Pavasovic V; Rao A; Bartram J; Vora A; Chiesa R; Silva J; Rao K; Bonney D; Wynn R; Pule M; Hough R; Amrolia PJ
Blood; 2024 Jan; 143(2):118-123. PubMed ID: 37647647
[TBL] [Abstract][Full Text] [Related]
25. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
26. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
27. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
28. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
Becerril-Rico J; Delgado-Montes YA; Ortiz-Sánchez E
Leuk Lymphoma; 2023; 64(11):1822-1831. PubMed ID: 37548560
[TBL] [Abstract][Full Text] [Related]
29. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
31. In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.
Safarzadeh Kozani P; Safarzadeh Kozani P; O'Connor RS
Mol Cancer Ther; 2021 Jul; 20(7):1223-1233. PubMed ID: 33903140
[TBL] [Abstract][Full Text] [Related]
32. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
[TBL] [Abstract][Full Text] [Related]
33. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
34. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
35. A novel full-human CD22-CAR T cell therapy with potent activity against CD22
Tan Y; Cai H; Li C; Deng B; Song W; Ling Z; Hu G; Yang Y; Niu P; Meng G; Cheng W; Xu J; Duan J; Wang Z; Yu X; Feng X; Zhou J; Pan J
Blood Cancer J; 2021 Apr; 11(4):71. PubMed ID: 33839735
[No Abstract] [Full Text] [Related]
36. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
37. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
Hucks G; Rheingold SR
Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
[TBL] [Abstract][Full Text] [Related]
39. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
40. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
Tan Y; Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Yu X; Chang AH; Feng X
Cancer Immunol Immunother; 2021 Jul; 70(7):1979-1993. PubMed ID: 33416942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]